Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial
Borlaug B, Testani J, Petrie M, Wang Z, Cunningham J, Adams K, Amir O, Bělohlávek J, Bocchi E, Freitas A, Hominal M, Kadokami T, Merkely B, Miller C, Nuñez J, Verma S, Yilmaz M, Oru E, Sam F. Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial. Nature Medicine 2025, 1-9. PMID: 40887551, DOI: 10.1038/s41591-025-03939-6.Peer-Reviewed Original ResearchEstimated glomerular filtration rateLA reservoir strainLong-acting formHeart failureReservoir strainNT-proBNPKidney functionHuman relaxinRenal serious adverse eventsN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptidePhase 2 randomized trialNT-proBNP levelsPreserved Ejection FractionSerious adverse eventsGlomerular filtration rateDouble-blindEjection fractionSecondary endpointsMulticenter trialNatriuretic peptideDecompensated HFpEFLA functionHF hospitalizationAdverse events
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply